Alternatives to Lunit

Volpara Health software is utilized by various facilities, including leading cancer screening centers in the United States, to facilitate the early detection of breast cancer. Mammography technologists depend on this software to enhance the quality of mammograms. Recognized as the most scientifically validated screening tool in the breast health sector, Volpara provides essential evidence at critical moments. It offers access to comprehensive patient data, enabling more accurate assessments of breast cancer risk. Each analyzed image contributes to refining our algorithms for early detection of the disease. Your support is crucial in promoting additional screening or genetic tests for patients. The platform allows for the creation of tailored worklists and reports according to individual preferences. Users can simultaneously view statistics and lists from a single interface, making the process more efficient. Communication can be standardized across patients, referrers, and insurers, ensuring clarity and consistency. Furthermore, it enhances the delivery of result letters by incorporating thumbnail images of mammograms, making the information more engaging and informative. This multifaceted approach ultimately promotes better patient care and outcomes in breast health.

Mamosis offers a cutting-edge AI-powered cancer diagnosis solution that accelerates and improves diagnostic accuracy by analyzing complex medical images and wellness metrics. The platform’s deep learning algorithms, developed with input from clinical experts, identify subtle patterns and anomalies that aid in early cancer detection. Mamosis delivers detailed, easy-to-interpret reports quickly, allowing clinicians to initiate timely interventions. The user-friendly interface streamlines the diagnostic process, enabling secure uploads and fast analysis, saving valuable time in clinical settings. With stringent data encryption and privacy protocols, patient information is protected at every step. Mamosis not only aids medical professionals but also empowers individuals by providing personalized health insights for proactive wellness management. The software integrates seamlessly into existing workflows, enhancing efficiency without disrupting daily operations. By fostering collaboration between AI and human expertise, Mamosis drives more accurate diagnoses and improved patient care.

Enhancing the care quality and outcomes for individuals battling cancer necessitates a cooperative effort among healthcare providers, researchers, cancer institutions, and the patients themselves. Oncora's user-friendly software platform empowers all parties involved to gather and utilize real-world data, thereby facilitating informed healthcare decisions that prioritize patient welfare. Our solutions are specifically designed for healthcare professionals who are committed to advancing cancer treatment results. By simplifying workflows, alleviating documentation challenges, and optimizing care through smart software solutions, we enable a more efficient healthcare experience. Our intuitive tools allow for the capture and visualization of regulatory-grade real-world data, essential for informed decision-making. With sophisticated reporting capabilities, you can measure quality and enhance operations to elevate patient care. Engaging in rigorous clinical research alongside leading cancer care experts further reinforces our commitment. The intuitive, web-based software we offer is tailored to meet the needs of your cancer center, providing data and tools that expedite clinical breakthroughs and innovations. Ultimately, our mission is to transform cancer care through technology and collaboration, ensuring that patients receive the highest standard of care available.

Ibex Medical Analytics stands at the forefront of AI-driven cancer diagnostics within the field of pathology. Our diverse team comprises entrepreneurs, data scientists, software engineers, and medical professionals united in our mission to revolutionize cancer diagnostics through artificial intelligence, ultimately enhancing patient care. As the volume of tests continues to rise annually, pathologists face significant challenges in delivering precise and timely analyses. To address this, Ibex harnesses the power of AI to create clinical-grade solutions that aim to identify cancer with the same level of accuracy as a human pathologist. The Galen Platform employs advanced algorithms to scrutinize images, detect and classify cancer in biopsy samples, and highlight other clinically significant findings, thereby assisting pathologists in minimizing diagnostic errors while streamlining their workflow. Notably, Ibex’s Galen™ Prostate and Galen™ Breast solutions represent the pioneering AI-based cancer detection tools integrated into routine clinical practice in pathology labs, showcasing proven efficacy in uncovering previously missed cancer cases. As we continue to innovate, our commitment to improving cancer detection and patient outcomes remains unwavering.

Riverain Technologies has developed ClearRead Xray, a suite of five applications that have received FDA clearance, aimed at improving the speed and precision of interpreting chest X-rays within healthcare settings, all without the need for extra equipment, procedures, or exposure to radiation. This innovative platform utilizes specialized suppression technology to create a clear view of the chest, which significantly aids in the swift and precise identification of cardiothoracic conditions. Among its standout features are the generation of bone-suppressed images that enhance visualization, the ability to spot potential lung cancer nodules, a decrease in the time required to read portable X-rays, automatic comparisons with previous examinations to emphasize changes, and compatibility across various imaging devices and protocols throughout the enterprise. Additionally, the ClearRead Xray Bone Suppress feature notably enhances soft tissue visibility by minimizing the presence of bone structures in digital images, thereby assisting radiologists in uncovering nodules that may have previously gone unnoticed. This comprehensive approach not only boosts diagnostic capabilities but also streamlines workflow in busy medical environments.

Accelerating the speed, precision, and affordability of cancer diagnoses is crucial, especially considering that one in three individuals will face this disease in their lifetime. Unfortunately, the current diagnostic process is often hindered by slow and costly methods, primarily due to the lack of advanced automated tools that support healthcare professionals. Qritive addresses this challenge by offering an AI-driven solution designed to assist physicians in analyzing both microscopy images and textual patient data efficiently. This innovation not only enhances the effectiveness of hospitals in diagnosing cancer but also contributes to significant cost savings. Additionally, Pantheon serves as a CE-marked, vendor-agnostic digital pathology platform that facilitates the complete digitization of pathology lab workflows and telepathology. It also supports comprehensive report generation and offers a robust platform for AI-driven analysis of whole-slide images in pathology. This technology is particularly adept at distinguishing between a variety of benign conditions and malignant diseases within breast tissue, which is vital for timely and accurate treatment. In doing so, it plays a pivotal role in transforming the landscape of cancer diagnostics.

Numerous choices in cancer treatment are fraught with uncertainty, and existing resources fail to assist a significant number of patients effectively. As a result, this situation contributes to preventable fatalities and the loss of billions in healthcare expenditures. Our team, which consists of experts from both computer science and oncology, is dedicated to addressing the critical challenges in cancer care using artificial intelligence. We are developing clinical-grade deep learning models that evaluate individual patient profiles and offer valuable guidance to oncologists during their decision-making processes. By placing oncologists at the forefront of our AI development, we ensure that the insights generated are not only interpretable but also actionable. Collaborating with leading academic medical institutions and community oncologists, we aim to tackle important clinical questions to improve patient outcomes. Ultimately, our goal is to enhance decision-making in cancer care and reduce the associated burdens on patients and healthcare systems.

Qure.ai's qLC-Suite is a cutting-edge AI-driven tool aimed at improving the early identification and management of lung nodules, which is crucial for prompt lung cancer intervention. This solution delivers accurate measurements, thorough characterization, and 3D imaging of lung nodules, ensuring that opportunities for early treatment are not overlooked. It is capable of supporting both incidental and targeted screenings by efficiently identifying nodules and calculating their volume with just one click. Moreover, the system monitors volumetric changes over time, providing valuable insights into nodule development. The qLC-Suite is designed to integrate smoothly into current workflows, offering quick analysis and reporting that assist healthcare professionals in their decision-making processes. In addition to its analytical capabilities, it serves as a comprehensive platform for managing lung nodules, facilitating care coordination through intelligent prompts, providing hardware-agnostic image viewing for AI-enhanced chest X-rays and CT scans, enabling seamless sharing of scans across departments, and allowing for tailored notifications for cases of concern. Overall, qLC-Suite represents a significant advancement in lung cancer care, promoting timely interventions that can ultimately save lives.

Omda Cytodose, an oncology medication management solution from Omda, employs clinically validated protocols along with patient-specific parameters to ensure safer and more effective treatments for individuals battling cancer. This innovative system enhances the quality of care provided to oncology patients by fostering a seamless and collaborative treatment process among healthcare professionals, including doctors, pharmacists, and nurses. Omda Cytodose is designed to support a comprehensive range of adult and pediatric cancers, accommodating various medical treatments such as chemotherapy, immunotherapy, hormone therapy, and additional supportive medications. Initially created by a team of clinicians at one of Norway's premier cancer centers and introduced in 2001, Omda Cytodose has gained widespread adoption across healthcare regions in the Nordic countries, leading to the fulfillment of millions of medication orders. With a robust 15-year history marked by stability, reliability, and safety, the system is meticulously configured with chemotherapy protocols that reflect both national and international guidelines. This ensures that patients receive the most up-to-date treatment options available, further enhancing their chances of successful outcomes.

Carevive provides a cancer care management platform that is integrated with electronic health records (EHR) to improve patient outcomes across the entire cancer treatment process. This innovative platform streamlines treatment planning by gathering patient preferences, evaluating interests in clinical trials, and tackling both physical and psychosocial challenges to enhance decision-making processes. During the active treatment phase, Carevive supports remote monitoring of symptoms through electronic patient-reported outcomes (ePROs), offering personalized symptom management plans and evidence-based pathways that aim to elevate quality of life and minimize hospital admissions. After treatment concludes, the platform continues to monitor patient-reported late effects and organizes essential care, which includes diagnostic assessments to identify new or recurring cancers. Furthermore, Carevive's analytics provide insights into aggregated patient experience data, aiding in ongoing quality enhancement and contributing to practical research in oncology. This comprehensive approach ensures that patients receive holistic support throughout their cancer journey, ultimately leading to better health outcomes.

Aiforia provides advanced deep learning and cloud-based solutions to pathologists and researchers in both preclinical and clinical laboratories, enhancing their capabilities in image analysis and workflow efficiency. By enabling scientists to discover new disease biomarkers and assisting R&D professionals in accelerating the market introduction of innovative drugs, Aiforia plays a crucial role in improving cancer diagnostic accuracy while revolutionizing healthcare from the initial discovery phase through to diagnosis. For clinical pathology laboratories seeking to boost efficiency and elevate the precision of their diagnoses, the Aiforia Clinical Suites present a comprehensive range of AI-driven diagnostic tools, intelligent visualization, quality control, and automated pre- and post-screening functionalities. We are in the process of developing specialized Suites targeting some of the most common cancers globally and have achieved CE-IVD certification for our AI solutions in lung and breast cancer, positioning us as a leader in diagnostic innovation. Our commitment to enhancing patient outcomes through technology underscores the transformative potential of our offerings in the healthcare sector.

The product evaluates a patient's risk level to create a tailored digital screening plan, ensuring more reliable follow-up recommendations and enhancing diagnostic accuracy. This strategy is particularly effective in identifying cancers in women who are at heightened risk. WRRisk integrates a fully digital breast cancer risk assessment that utilizes patient-completed digital forms alongside a density evaluation to generate a comprehensive risk scorecard. By automating numerous manual processes, such as form collection and letter creation, WRRisk streamlines the management of breast risk programs, eliminating the need for paper documentation. This innovative product empowers both patients and healthcare providers with essential information, enhancing the overall care experience. Additionally, WRRisk provides calculations for ten-year and lifetime risk, as well as assessments based on secondary density metrics.

CADU, a cloud-enabled AI solution created by Odin Vision, is designed to aid in identifying and characterizing dysplasia in individuals with Barrett’s oesophagus during gastroscopy. The system evaluates areas that visually resemble Barrett’s oesophagus and offers insights to help clinicians determine whether the tissue is dysplastic or non-dysplastic. By improving the decision-making process for endoscopists and expediting the examination of the oesophagus, CADU proves to be both time-efficient and cost-effective. Additionally, it functions on a platform that is vendor-neutral, facilitating its use with various endoscopic equipment. The system is CE marked and holds UKCA approval; however, it is not available for commercial sale in the United States. CADU has been adopted in clinical environments, including University College London Hospitals, aiming to enhance the detection of early oesophageal cancer, which can often be difficult to identify due to the subtle nature of initial lesions. Its implementation represents a significant advancement in the early diagnosis of this serious condition, highlighting the importance of technology in modern medicine.

Inspirata is a specialized oncology data and analytics platform built to help cancer programs improve care delivery and operational performance. It leverages AI-driven technology to automate cancer casefinding, data extraction, and reporting with high accuracy. The platform supports compliance with regulatory requirements while significantly reducing manual registry work. Inspirata transforms unstructured clinical data into actionable insights that fuel research and clinical decision-making. Real-time data access helps improve trial accrual and ensures equitable patient access to clinical studies. Patient navigation tools support coordinated care from screening to survivorship. By improving efficiency, Inspirata allows staff to focus on higher-value patient and research activities. The platform integrates seamlessly with major EHR and clinical systems. Trusted by hundreds of hospitals, Inspirata delivers measurable improvements in oncology operations. It helps cancer centers maximize impact while minimizing cost and complexity.

Efficiently generating reports for NGS-based clinical tests necessitates a well-established and sophisticated platform that can automatically prioritize variants, interpret clinical data, and create comprehensive reports. Strand Omics serves as a rapid, HIPAA-compliant cloud platform that enhances our clinical diagnostics efforts, having been refined over four years through the analysis of more than 10,000 clinical reports and numerous peer-reviewed studies. This platform integrates advanced bioinformatics algorithms with curated databases, intuitive visualization tools, and robust reporting features. It is designed with specialized workflows tailored for both rare inherited conditions and somatic tumor profiling assays. Additionally, the system boasts a library of over 10,000 somatic variants that have been curated for their oncogenic potential, alongside 100 genes selected for their druggability across various cancer types, as well as 500 drugs that have been validated for efficacy against multiple cancers. Furthermore, its comprehensive approach ensures that healthcare professionals have access to critical data, ultimately facilitating informed decision-making in patient care.

Paige's offerings have the potential to revolutionize the practice of pathologists by instilling greater certainty in diagnoses. The company is committed to pioneering a new era of clinical tools and predictive assessments that empower pathologists while redefining the field of oncology. With its innovative AI solutions, Paige paves the way for the future of pathology. The Paige Platform serves as a comprehensive, secure solution that ensures interoperability with laboratory information systems (LIS), integrates multiple scanners, offers cloud storage, facilitates case management, enables image review through FullFocus®, and incorporates advanced AI applications. The Paige Prostate suite of AI tools is specifically designed to aid pathologists in identifying suspicious areas, grading and quantifying tissue samples, and assessing perineural invasion (PNI) in prostate needle core biopsies. Similarly, the Paige Breast suite of AI applications supports pathologists in evaluating breast cancer by enabling the identification of malignancies in breast biopsies and the detection of metastases in lymph nodes associated with breast tissue. Collectively, these advancements not only enhance diagnostic accuracy but also improve patient outcomes in oncology.

Explore our efficient screening tools designed to identify patients at a high risk for breast, colorectal, and other types of cancer. Progeny Clinical streamlines the management of family histories, risk assessments, and treatment options for your patients. You can gather family history information online and automatically create pedigrees prior to the clinic appointment. Modify existing pedigrees or create new ones at any time. Execute validated hereditary cancer risk assessment models with a single click, eliminating the need to re-enter data. Simplify the process by ordering genetic testing through Ambry Genetics. Monitor and analyze results from any laboratory without leaving the software environment. Enhance efficiency by generating letters, consultation notes, reports, and documents using custom templates that incorporate patient data fields. Utilize pre-configured or tailored data input screens to swiftly create custom queries and spreadsheet reports. Moreover, you can integrate a hyperlink within your electronic medical record to conveniently access the patient’s latest pedigree. This innovative approach not only saves time but also optimizes patient care and enhances workflow efficiency.

Enhance the Patient Journey by actively engaging, educating, and empowering individuals through improved health communications. Utilize a Patient Engagement Platform to tailor optimal care plans for various medical pathways, such as prostate and breast cancer. Develop a Patient Engagement Pathway that organizes communication strategies in accordance with each care plan's requirements. Streamline the organization of communications by creating or sourcing a variety of supportive materials, including messages, documents, and videos, that correspond to different phases of the care plan. Establish clear communication rules that specify who receives which communications and at what times, ensuring timely delivery of essential information. Integrate new patients into the system effortlessly by matching their specific needs with the appropriate pathway. Finally, centralize all patient-facing communications in one location, allowing for the efficient dissemination of messages, documents, forms, videos, and health widgets. By doing so, healthcare providers can enhance the overall patient experience and foster better health outcomes.

We assist in standardizing the contouring of organs at risk and automating segmentation in radiotherapy, which enhances the efficiency of cancer treatment planning. By adhering to established consensus guidelines, we ensure that the contours you create are more reliable. Every clinic requires a robust standard, and we take charge of implementing it on your behalf. Our fully automated 3D organ models can be generated in just a minute, significantly reducing the time spent on manual processes. This allows you to concentrate on more intricate delineation tasks rather than squandering valuable resources. Manual contouring often suffers from inter-observer variation, a challenge we address by providing consistent results. As a result, you can effectively reduce the negative consequences that stem from errors in the delineation of anatomical structures. With a single software solution that complies with GDPR regulations, the process of radiotherapy treatment planning has never been more straightforward. Our cloud-based AI model is designed to integrate effortlessly with all hospital systems, enhancing your workflow. MVision AI stands out as an innovative provider of cloud-based software services specifically for radiotherapy treatment planning, setting a new standard in the field. This approach not only improves accuracy but also promotes better patient outcomes in the long run.

CureMetrix harnesses the capabilities of Artificial Intelligence (AI) to enhance technology aimed at bettering disease detection and boosting cancer survival rates on a global scale. Our mission is centered on equipping radiologists with state-of-the-art tools that facilitate their assessment of mammograms, ultimately leading to enhanced clinical and financial results, as well as greater confidence for imaging centers, healthcare systems, and the patients they serve. Initial research involving thousands of images indicates that our innovative algorithm has the potential to decrease false-positive rates, which can help avoid unnecessary follow-up procedures and alleviate patient anxiety. We are committed to creating advanced technology that allows healthcare providers to detect even the smallest changes more swiftly and accurately than ever before. Our image analysis platform is specifically engineered to enhance the evaluation of dense breast tissue through mammography, thereby improving diagnostic accuracy and patient care. As we continue to refine our technology, we remain focused on the impact it can have on the future of medical imaging and patient outcomes.

Concentriq, our advanced AI-driven software platform, operates at the crucial crossroads of digital and computational pathology, merging essential functionalities for routine pathology tasks with robust AI tools that enhance innovations and elevate patient care quality. Pathology laboratories around the globe are acutely aware of the contemporary hurdles, which include an escalating cancer incidence, a shortage of trained pathologists, diminishing reimbursement rates, and the urgent need for modernization. In this context, with one billion pathology slides projected to transition to digital formats annually, generating enormous volumes of new data and insights, the urgency to act is undeniable. Digital pathology equips today’s progressive pathology organizations with the resources necessary to tackle these challenges effectively, thereby revolutionizing our operational methods and significantly impacting the fields of medicine and patient treatment. As this transformation unfolds, the potential for improved diagnostics and enhanced patient outcomes continues to grow exponentially.

Color delivers one of the most user-friendly, high-quality genetic testing services currently on the market, examining genetic markers linked to the likelihood of developing prevalent cancers and heart diseases, as well as how individuals metabolize specific medications. Our comprehensive range of services, tools, and expertise is designed to facilitate the enrollment of new patients and guide them through personalized care journeys that evolve over time. By taking a holistic approach to patient health, we integrate genetic data, personal and family medical histories, along with lifestyle and behavioral factors to identify and suggest tailored care options or solutions that align with each patient's unique risk profile. This multifaceted strategy ensures that patients receive relevant recommendations that can significantly impact their health outcomes.

Recursion is a leading TechBio innovator using artificial intelligence to radically improve how new medicines are discovered and developed. The company was founded on the idea that images of cells could be used to train AI systems to understand disease biology at scale. By combining data, machine learning models, and powerful computing, Recursion works to overcome the inefficiencies of traditional drug discovery. Its Recursion OS platform connects massive proprietary biological datasets with automated experimentation and AI-driven insights. This approach has produced a growing pipeline of potential therapies for oncology and rare diseases with high unmet medical needs. Recursion has demonstrated significant gains in speed, efficiency, and cost reduction compared to conventional pharmaceutical methods. Strategic partnerships with pharmaceutical companies and technology leaders expand the reach of its platform. The company also collaborates with NVIDIA to power its discovery efforts using BioHive-2, one of the most advanced supercomputers in biopharma. Together, these capabilities position Recursion as a leader in AI-driven drug discovery. Its ultimate goal is to deliver better medicines to patients through precision design and data-driven science.

Speeding up the creation of crucial medications and ensuring that patients worldwide can access top-notch cancer treatment and research equally. Our technology is transforming how patients access cutting-edge medicines and participate in clinical trials. FICS is a groundbreaking software solution that facilitates the gathering of regulatory-compliant data throughout patient treatment. By integrating previously isolated and non-interacting applications into a comprehensive, seamless platform, FICS is making clinical trials more efficient, quicker, and of superior quality, ultimately enhancing patient outcomes in significant ways.

Noona® offers a comprehensive management solution for patient outcomes that actively involves patients in their treatment through immediate symptom reporting and monitoring, enhanced clinical workflows that support evidence-based practices, and access to extensive data insights for improved ongoing care management. Patients have the freedom to report their symptoms, fill out questionnaires, and engage with their healthcare teams whenever they wish. This approach enables care teams to gather highly specific and detailed data tailored to each patient's diagnosis and treatment plan, facilitating better-informed decision-making. With the benefit of automated prioritization, healthcare providers can identify and respond to patients who require urgent attention. The platform features over 31 treatment modules that encompass more than 97 prevalent cancer types, complemented by 244 algorithms that assess symptom severity according to established guidelines. Additionally, its remote deployment capabilities ensure quick implementation and immediate access for patients to start using the system. This innovative solution ultimately enhances the overall quality of patient care and outcomes throughout the treatment journey.

The integrated mammography viewer allows for ergonomic reading of a diverse range of breast imaging studies alongside other specialty examinations, all conveniently located in one interface. By streamlining workflows, it facilitates quicker reading in high-volume settings, resulting in increased patient throughput. The incorporation of Artificial Intelligence enhances physician efficiency, reduces false negatives in cancer detection, and contributes to the quality assurance of imaging results. A holistic telemammography solution serves as a vital link to expanding access to breast expertise, ultimately leading to improved diagnostic accuracy and patient outcomes. The NovaMG PRO can function as an independent workstation compatible with any PACS or mammography technology. Additionally, the breast care workflow module is included within NovaPACS EI, and current users can activate it in just a few minutes, enhancing their existing systems. This integration not only simplifies the process but also empowers healthcare professionals to deliver better care to patients.

No matter the scale of your clinic or your location, MOSAIQ Plaza* equips you with the essential digital tools to provide exceptional multidisciplinary care for your patients—ensuring consistency, reliability, and security throughout their journey from diagnosis to survivorship while generating valuable real-world evidence. Elekta has introduced robust solution packages designed to boost your team's ability to provide care and optimize treatment workflows, allowing you to concentrate on your primary focus: your patients. As we pave the way for the future of multidisciplinary cancer care, MOSAIQ 3 establishes new benchmarks in oncology workflow and information management. Experience the advantages of effortless access to the MOSAIQ Plaza environment, which leads to remarkable efficiencies and a more streamlined operational experience, ultimately enhancing patient outcomes and satisfaction.

Inactivity is a significant contributor to various lifestyle diseases, such as diabetes and stress-related conditions. These health issues often arise from a combination of poor dietary choices and insufficient physical activity, which can lead to obesity. Moreover, engaging in unhealthy habits like smoking increases the risk of developing serious illnesses, including cancer and cardiovascular diseases, as well as complications such as blood clots linked to elevated cholesterol levels. Stress, another prevalent lifestyle disease, can impact individuals regardless of their employment status, manifesting as a feeling of inadequacy in meeting personal or societal expectations. Furthermore, loneliness, which is relatively common in Nordic countries, can exacerbate feelings of isolation and may lead to depression, highlighting the importance of social connections for mental well-being. It is crucial to address these interconnected issues to promote a healthier lifestyle and overall quality of life.

Enhance the effectiveness and efficiency of cancer care throughout various healthcare environments. Developed in close partnership with cancer specialists, iKnowMedSM serves as an electronic health record (EHR) that seamlessly offers essential patient information precisely when it’s needed, accessible on nearly any device. Featuring the latest advancements in user interface design and an unparalleled mobile platform, iKnowMed EHR delivers extensive point-of-care treatment decision support alongside customizable features that easily fit into current workflows. Empower your patients with thorough clinical assistance by utilizing a constantly refreshed repository of oncology treatment protocols, drug availability, and clinical outcomes. Gain access to evidence-based clinical guidelines and pathways precisely when required, ensuring timely and effective decision-making. Furthermore, keep your treatment options current by integrating data on treatment expenses, insurance coverage, and reimbursement information, thereby supporting both patients and healthcare providers in navigating the complexities of cancer treatment. In doing so, practices can significantly improve patient outcomes and streamline the overall care process.

My Care PlusSM enhances the healthcare experience by fostering a personal connection that allows patients to take charge of their health journey. Through the user-friendly portal, individuals can easily access their personal health records, communicate with their healthcare providers, and explore a newly expanded repository of educational resources designed for patients. Patients are granted the ability to review their comprehensive care plans, along with vital health information and educational materials on conditions and medications sourced from reputable cancer organizations, accessible at any time and from any location. They can also utilize secure messaging to address non-urgent inquiries or send broadcast messages to all patients, ensuring effective communication. To boost patient engagement with the portal, customizable marketing resources, videos, and other tools are available to raise awareness of its advantages. Additionally, the platform supports healthcare practices in achieving Meaningful Use objectives by integrating all necessary features to fulfill both stage 1 and stage 2 requirements. Furthermore, it offers robust clinical decision support, along with performance analytics to enhance practice efficiency and patient care. With this comprehensive suite of services, My Care PlusSM not only improves patient interactions but also enhances the overall quality of care provided.

Our software products are crafted for simplicity and quick comprehension. User-friendly interfaces, developed in collaboration with Oncologists, are designed to maximize efficiency and save valuable time. We implement robust systems aimed at improving patient safety while introducing innovative modules that push the boundaries of research. Automation is at the heart of our solutions, facilitating everything from chemotherapy order planning to staff management. We provide a thorough solution tailored for cancer centers, optimizing the Oncology workflow seamlessly. With our platform, generating accurate chemotherapy orders is a swift and uncomplicated process. Our extensive protocol library boasts over 1000 regularly updated protocols. The system automatically calculates and confirms drug doses and infusion rates while being rigorously tested and CE marked for quality assurance. All doses are verified twice, and checks for drug-drug and drug-allergy interactions are included. Patient-drug matching is enhanced through QR coded labels, significantly reducing medication errors. Users can conveniently view the active chemotherapy order, patient diagnosis and stage, the latest lab results, and the chemotherapy flowsheet all on a single screen, ensuring a comprehensive overview at a glance. This streamlined approach promotes efficiency and safety in Oncology practice.

Achieve a comprehensive understanding of your research operations by utilizing a robust and standardized clinical trial management system that has been developed in partnership with prominent academic medical and cancer centers. Streamline billing designation processes to promote uniformity across various teams and systems. Enhance your budgeting strategies, ensure accurate routing of charges, and perform more effective audits and monitoring of billing compliance. This integrated approach provides deep visibility and insight into all elements of clinical research, particularly in financial management, thanks to collaboration with elite research institutions. Moreover, by connecting OnCore with your existing electronic medical records (EMR), including seamless integrations with Epic and Cerner, you can significantly boost patient safety, minimize redundant data entry, improve billing compliance, and elevate overall operational efficiency. Ultimately, this system not only simplifies processes but also fosters a more effective research environment.

The ARIA® oncology information system is designed to assist both medical and radiation oncology practitioners, including those utilizing proton therapy. It enables the review of clinical images, prescriptions, lab results, quality assurance, treatment outcomes, and much more. Additionally, it automates cancer staging in accordance with AJCC guidelines and allows for flexible management of treatment toxicities. With a strong emphasis on interoperability, ARIA ensures that patient data can be utilized effectively across various devices and platforms. It provides comprehensive support for HL7 and DICOM standards, simplifying the transfer of patient data between healthcare facilities. This system grants your teams immediate access to patient information, enhancing their ability to plan and make real-time adjustments as needed. Furthermore, ARIA OIS aids in optimizing image-guided treatment techniques by utilizing radiographic, fluoroscopic, and cone-beam CT images. It also documents activities to support evidence-based Pay-for-Performance initiatives while ensuring compliance with HIPAA regulations. By efficiently storing and organizing patient data and images, ARIA enables your teams to remain informed and dedicated to providing high-quality care for their patients. This innovative system ultimately streamlines workflows, allowing healthcare providers to focus on what truly matters: patient outcomes and well-being.

EDGE, a cloud-based Clinical Trials Management System, has been successfully integrated into the UK's clinical research infrastructure and the devolved countries. Currently, EDGE is used in 80% of England's NHS regions, Scotland, and Northern Ireland. EDGE is the leading research management system in the UK. EDGE was launched in 2000 and adopted by the National Cancer Research Network. It has seen tremendous growth and has a growing number international subscribers from countries which include Canada, Belgium, New Zealand, South Africa and India.

The microbiome plays a significant role in various diseases and health issues. Discover how Kaleido is pioneering a unique method to transform the potential of the microbiome into effective patient solutions. Comprising over 30 trillion microbes, the human microbiome includes a diverse array of organisms such as bacteria, viruses, archaea, and fungi that inhabit both the exterior and interior of the human body. In recent years, there has been a remarkable surge in research focusing on the microbiome's influence on human health, linking it to conditions such as cardiovascular disease, cancer, diabetes, Parkinson’s disease, and allergies. This intricate microbial community has been likened to a "newly discovered organ," highlighting its significance. Just as many human organs command substantial investments for therapies that modify physiology, the microbiome represents a largely unexplored territory in the realm of healthcare. Addressing this frontier could unlock new therapeutic avenues and enhance overall health outcomes.

By leveraging visual analytics through TIBCO Spotfire®, PerkinElmer Signals Translational offers a comprehensive suite of tools designed to harmonize, manage, search, aggregate, and analyze extensive datasets consistently for translational research, all while ensuring scalability. This platform, driven by TIBCO Spotfire®, supports precision medicine initiatives by providing an unparalleled solution for biomarker discovery and patient stratification. The Linear Mixed Effect App (LME) within Signals Translational empowers researchers to evaluate the influence of various factors on specific phenotypes, allowing for adjustments related to random variables during analysis. Furthermore, it enables the identification of genes significantly affecting cancer stage progression, irrespective of patient origins. Notably, the LME models excel at addressing issues such as missing values and outliers, making them a robust choice for discovering potential biomarkers. Consequently, the integration of these advanced analytics tools enhances the efficacy of translational research in identifying key biomarkers that can lead to more personalized treatment approaches.

TrueMedLIS is a cloud-based platform that combines laboratory information management and customer relationship management to streamline and automate various laboratory functions, ranging from sample collection and analysis to data interpretation and reporting, while catering to a wide array of fields such as infectious diseases, COVID-19, cancer genomics, pharmacogenomics (PGx), toxicology, hematology, and other specialized lab areas. By replacing outdated manual methods like paper-based faxes and isolated systems, it facilitates digital order management, provides user-friendly portals for both physicians and patients, and features dedicated interfaces for sales and lab administrators, all with the goal of boosting operational efficiency and minimizing data entry mistakes. Additionally, it seamlessly integrates with pre-existing systems such as billing services and pharmacy benefits management tools, offers real-time analytics along with customizable reporting options in various formats such as Excel and CSV, and is designed with a strong emphasis on security and round-the-clock customer support. This comprehensive approach not only enhances laboratory productivity but also contributes to more accurate and timely patient care outcomes.

Founded in 2016, Infervision stands at the forefront of AI-driven medical technology, dedicated to enhancing multidisciplinary healthcare services and operations through innovative artificial intelligence solutions. Their advanced AI offerings are designed to assist healthcare professionals across a spectrum of tasks, including disease screening, diagnosis, intervention, treatment, patient management, and medical research. Among their array of solutions, InferRead CT Lung specializes in detecting lung nodules from chest CT scans, while InferRead DR Chest focuses on identifying chest abnormalities via X-ray imaging. Moreover, InferRead CT Coronary is tailored for recognizing coronary artery stenosis during coronary CT angiography, and InferRead CT Stroke is adept at triaging hemorrhages from brain CT scans. The company also provides InferRead CT Bone for spotting chest fractures in CT images and InferRead CT Pneumonia for diagnosing and managing pneumonia cases. Beyond these, their offerings extend to InferOperate, which facilitates 3D reconstruction for thoracic, liver, and urological surgical procedures, and InferCare, a tool designed for effective patient management and image follow-up. Additionally, InferScholar acts as an AI-enhanced resource for medical research, further solidifying Infervision's commitment to transforming healthcare through AI technology. This comprehensive suite of solutions positions Infervision as a pivotal player in the evolution of medical practices.

Finding suitable cases for your law firm can be both expensive and labor-intensive, and assessing whether to proceed with a case often entails extensive due diligence. Darrow simplifies this process by linking you to significant cases, enabling you to make more informed and quicker decisions. Every day, countless individuals face legal rights violations that often go unnoticed, ranging from harmful air pollution that can lead to cancer to privacy infringements that jeopardize private data. For legal professionals, the task of navigating through vast amounts of information to uncover critical evidence can be overwhelming. Darrow ensures that each case is paired with the appropriate firm based on jurisdiction and area of expertise, guaranteeing you receive the most relevant referrals. Additionally, Darrow produces analytical intelligence reports filled with crucial details such as evidence, potential damages, class size, and legal precedents to aid in your strategic planning. Furthermore, its advanced predictive AI assesses the financial implications of each case throughout different stages of the legal process, eliminating uncertainty. This innovative approach not only streamlines case management but also empowers attorneys with the insights needed for successful outcomes.

Symplectic Grant Tracker offers research funding organisations efficient, meaningful grants management. We specialise in enabling mission-driven organisations to make smart funding decisions thanks to our experience streamlining grant management and administration for more than 15 years. Grant Tracker is a tool created to aid with research funding needs. It has features to assist applicants, funders, reviewers, and committees in working effectively throughout the grants management lifecycle. Over 50 funding organisations, including The Howard Hughes Medical Institute (HHMI), National Institute for Health Research (NIHR), Versus Arthritis, Macmillan Cancer Support, and The Leverhulme Trust, use Symplectic Grant Tracker to support their pre- and post-award procedures. These organisations collectively award more than $2 billion annually.

VSClinical facilitates the clinical analysis of genetic variants in accordance with ACMG and AMP guidelines. Its structured workflow supports adherence to the American College of Medical Genetics (ACMG) standards, which are essential for identifying and categorizing pathogenic variants related to inherited disease risk, cancer susceptibility, and rare disease diagnosis. The combined ACMG/AMP guidelines for variant interpretation establish a framework for scoring variants and categorizing them into one of five classification levels. Implementing these guidelines necessitates a thorough examination of annotations, genomic contexts, and pre-existing clinical insights for each variant. VSClinical streamlines this process by offering a customized workflow that evaluates each relevant criterion and supplies comprehensive bioinformatics, literature references, and clinical knowledgebase evidence to aid in the scoring and interpretation of variants. This innovative approach is designed to enhance the efficiency of variant scientists as they navigate the complexities of variant processing and analysis. Overall, VSClinical stands out as a vital tool for accelerating the understanding and classification of genetic variants in clinical settings.

The foundational aspect of our immunotherapy approach lies in our comprehension of antigens and neoantigens, particularly in identifying which variations will be transcribed, translated, processed, and subsequently displayed on the surface of cells via Human leukocyte antigen (HLA) molecules, thus making them recognizable to T cells. We achieve this by employing Gritstone EDGETM, a unique platform powered by machine learning. Creating cancer immunotherapies that incorporate tumor-specific neoantigens proves challenging, mainly because tumors consist of numerous mutations, yet only a fraction of these lead to genuine tumor-specific neoantigens. To tackle this complexity, we have developed EDGE's cutting-edge integrated neural network model, trained with millions of data points gathered from a diverse range of tumor and normal tissue samples across various patient ancestries. This extensive training allows us to enhance the accuracy of neoantigen identification and improve the effectiveness of our immunotherapy strategies.

Transform your single-cell RNA sequencing data into actionable insights using Cellenics software, which is hosted by Biomage as a community instance of this open-source analytics tool developed at Harvard Medical School. This platform empowers biologists to delve into single-cell datasets without the need for coding, while facilitating collaboration between scientists and bioinformaticians. Within just a few hours, it can convert count matrices into publication-ready figures, integrating effortlessly into your existing workflow. Cellenics is designed to be fast, interactive, and user-friendly, as well as being cloud-based, secure, and scalable to meet various research needs. The community instance provided by Biomage is available at no cost for academic researchers working with smaller to medium-sized datasets, accommodating up to 500,000 cells. Currently, over 3000 academic researchers engaged in studies related to cancer, cardiovascular health, and developmental biology are utilizing this powerful tool. This collaborative environment not only enhances research capabilities but also accelerates the discovery process in various scientific fields.

A platform designed for life scientists focusing on data science. Transform your microbiome investigations into actionable insights and expedite the introduction of innovative, safe, and efficient products to the marketplace. By integrating appropriate data science methodologies and collaborative tools, you can achieve swift progress in cancer treatment advancements. Enhance your research efforts, foster innovation, and create substantial value through the implementation of effective digital technologies that enhance agricultural output. You can easily import both small and large datasets, organizing them using our provided templates or customizing your own structure. Our format inference technology generates parsing functions while allowing you to make adjustments without any coding required. Utilize our user-friendly import interfaces or command-line tools for bulk data uploads. Your information represents more than mere data points; Solvuu automatically provides pertinent summary statistics and produces engaging, interactive visualizations. Dive deep into your data for immediate insights and manipulate it freely as necessary, ensuring a thorough understanding of your research findings. With this platform, you will efficiently harness the power of your data for impactful results.

Mosio allows research teams to improve subject adhesion, communications, data collection, and communication on mobile's most popular channel, text messaging. Our software helps research teams communicate more efficiently with participants by delivering interactive elements to mobile phones and messaging automation. WHO CAN WE HELP? + Clinical Trial Sponsors (Pharma & Biotech) + Cancer Centers and Clinical Research Organizations + NIH-Funded Studies + Public Health Agencies + Clinical Trial Managers/Directors and Clinical Operations Managers/Directors. Clinical Project Managers. Principal Investigators. Clinical Research (Study). Coordinators. All research staff who regularly communicate with study participants. BENEFITS + Interactive medication reminders and medication compliance alerts + Automate data collection. + Increase engagement and adherence. + Get SMS appointment reminders to fix your no-show problem. + Increase retention with automated check ins